



SINGAPORE – ISRAEL TECHNOLOGY MEETUP


BREAKTHROUGH INNOVATION | 2022






Enigmatos provides automotive cybersecurity and data utilization solution for fleets.


Our technology includes the ability to efficiently upload and analyze vehicle data and build a vehicle profile that facilitates identifying any suspicious cyber activity on the vehicle’s network. In addition, we use the uploaded data to present telematic information and critical alerts info as well as predictive maintenance to make sure the most efficient and continues usage of the fleet



Enigmatos solution is purpose-built for operational fleets and can be implemented via integration with existing systems.




Unique Selling Points: Enigmatos' tools and technology enable an End-to-End solution for all types of vehicles regardless of the vehicle manufacturer.



Go To Market strategy: Geo-location and telematics companies, car importers and dealers, large fleets, hardware vendors and 3rd parties interfacing with the EnigmaOne platform.

Proof of capability: The company is currently in the process of implementing the technology in several vehicle fleets: Dan Public Transportation (1,300 buses), Philip Morris Israel (the entire operational fleet) and more.



[TheMarker Article.](#)

Additional POC: Ashdod Port, the Innovation Lab of Renault Nissan, the Ministry of Transport (Ayalon Highways), ELTA, Alstom, IBI Canada, Ben Gurion University As part of the establishment of the Cyber Transportation Center – Enigmatos was chosen to be the supplier that will accompany the center.

[About the collaboration](#)



For more information : <http://www.enigmatos.com>



Sensifree is a medical device company, develops and manufactures advanced non-invasive hemodynamic monitoring products. Our products are designed to improve patient safety and reduce clinician's workload, by providing better situational awareness to patient's condition.





Inadequate BP monitoring leads to episodes of low blood pressure go unknown to clinicians. It has been shown that such low blood pressure episodes significantly increase the rate of post surgical cardiovascular complications – the leading cause for 30 days post operative mortality. This is important because BP can be modified and controlled by medications. Detection of those episodes and BP trends would allow timely intervention and improve the medical outcome.

Our first product, SentiCor-100, solves the unmet clinical need for adequate blood pressure monitoring in acute patients. SentiCor-100 augments the BP cuff by providing continuous BP readings.

SentiCor-100 is the world's first device that provides continuous non-invasive BP measurement for hospital use, utilizing the low-cost, ubiquitous fingertip PPG sensor. Our patented technology delivers high performance at an affordable price, giving excellent value to customers.


SentiCor-100 uses Sensifree's patented BP technology and is CE cleared (under new EU MDR).

For more information : www.sensifree.com






Lorin is a global player in LoraWAN networking and IoT solutions. Our goal is to establish the most extensive LoRaWAN network on the planet.




The company's mission is to harness IoT technologies and strategic partnerships with global players to deliver solutions to the most pressing challenges that threaten the sustainability of our planet.




We connect sensors to the internet of things and develop solutions for regional, national or global players.

We provide the most advanced tailor-made solutions for multiple industries and use cases, including remote areas.



We offer fire detection and prevention services, smart cities, buildings, and homes, smart retail and supply chains, pollution management, animal care and management, smart agriculture and farming, water monitoring and control, recycling waste management, and many more use cases.



Lorin has a few revenue streams: installation and service for IoT devices, communications generated through the Helium wireless network, and sale of gateways and IoT devices.



Lorin is developing projects in Europe, South Africa, the Philippines, and Central Asia.



For more information : www.lorinnetwork.com





TRIGONE
pharma

Transformative New Solutions for Urologic Diseases





Trigone Pharma, a clinical stage company, is developing innovative drug products to treat locally urinary diseases. Our first product TRG-100 addresses the unmet need for efficient, safe and localized treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). Our second product in development, TRG-140, is indicated for BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). The products are designed to significantly increase the local dwell time and exposure of the drugs to the target sites for days and weeks, representing a revolution in urology, and providing enhanced clinical activity.

Our Technology

Effective Prolonged Treatment

- Our localized delivery system acts continuously over days and weeks.
- Clinical results show efficacy and safety.
- Maximizing the efficacy of drugs that otherwise fall short of effect, by increasing the concentration at the target organ site while minimizing systemic adverse effects.
- Can deliver small & large molecules or including biologics.
- Can deliver drugs combination
- Solution transforming in-situ into soft solid after instillation.
- Soft solid undergoes erosion in urine bladder releasing the drug.
- IP –2 patent applications: National Phase & Provisional

For more information : www.trigonepharma.com



RHTLaw Asia
ONE across Asia





AIRONWORKS

AironWorks provides the next generation cybersecurity awareness training for employees utilizing our AI-based targeting phishing & social engineering simulation system.

The challenge:

Today, phishing is by far the most common type of cyber attack – over 90% of data breaches in 2021 occurred due to phishing attacks. As the software world is becoming more secure, targeting employees has become one of the more cost-effective ways for hackers to infect organizations with malware or gain access to sensitive info.

The current training solutions use basic phishing simulations with standard email templates, teaching employees that phishing attacks have one specific structure that is easy to identify.

But in reality, phishing and social engineering are continuously evolving real-time threats relying on human error.

Today, hackers don't use standard phishing scenarios but spend time researching and studying organizations to find real-time opportunities they can exploit with sophisticated social engineering attacks.

AironWorks to the rescue!




With AironWorks' targeted phishing simulation platform, you can train your employees to be better prepared against the modern hacker methodology.

The AironWorks system can study real-time information about our customers and utilize latest AI technology to generate highly targeted phishing simulations through a variety of attack vectors, essentially creating a virtual hacker that constantly targets our customers to find their weak "human" points.

The next generation AironWorks' security awareness platform allows our customers to:

- * Conduct AI-based targeting phishing simulation
- * Explore a wide array of possible attack vectors that hackers can use to target your organization
- * Get personalized training & result insights using the AironWorks survey system
- * Utilize the AironWorks AI power to also protect your employees from targeted phishing attempts in real time

For more information : www.aironworks.com



RHTLaw Asia
ONE across Asia








Amsel Medical is a pre-commercial medical device company that has successfully developed an innovative core technology, SCureClamp™, earning both FDA and CE Mark clearance. The company is addressing both civilian and military markets with broad IP protections and successful first-in-human clinical acceptance.

This unique minimally invasive, mechanical implantable clamping technology is delivered directly through a fine, (18 gauge) needle for permanent or temporary occlusion of tubular structures (e.g., arteries, veins, and ducts). The minimally invasive needle delivery results in less trauma for the patient and faster recovery time.

Amsel has several clinical applications with an initial >\$2B addressable market opportunity in the treatment of chronic venous disease and trauma. Over 80 million adults worldwide are affected by progressive venous disease often presenting with varicose veins and venous ulcers. Current treatment options fall short and typically destroy or remove the vein. Amsel’s SCureClamp is the first minimally invasive, needle delivered (guided by standard imaging technologies, e.g., ultrasound), permanent solution to solve this unmet need. It provides a new way of clamping tissue and occluding vessels and ducts - featuring IDOT - Interdigitation Occlusion Technology, that interleaves the clamping elements, minimizing damage to the clamped tissue while providing reliable sealing. The company has also received award of over \$2.5M in non-dilutive SBIR funding from the US military and is considered a sole-source provider to the DoD for its trauma solution. Amsel’s SCureTO™ is an evolution of the SCureClamp product and is being developed specifically for use in front-line military as well as civilian trauma scenarios. This temporary occluder is targeted at significantly reducing deaths associated with junctional non-compressible hemorrhage, which currently accounts for 60% of fatalities in military trauma cases. Today the majority of military fatalities occur in the prehospital environment. As a result, there is a need for a field deployable, minimally invasive, and effective tool to prevent exsanguination and aid in the urgent care of those wounded. This is core to Amsel’s mission to save limbs and save lives. Based on lessons learned in the military opportunities there exist opportunity to improve the control of external hemorrhage in the civilian sector as well.

While Amsel is focusing initially on Chronic Venous Disease and DoD Trauma (with non-dilutive funding), Amsel’s technology has great potential to be leveraged in a broad range of additional minimally invasive clinical applications including laparoscopic and robotic surgery.



For more information : www.amselmedical.com




TuriSafe™




Making the world a safer Place

A Global Data Base of Crime Locations.

TuriSafe™ Consolidates **Location-based Risks Management** Data taken from various official sources such as government's official sites, ministry of health, police crime map, municipals, security departments etc.




TuriSafe™ can be used as a Geolocation based platform (API) working at the background of a **Mobile Phone**. When the tourist/person enters a dangerous location, TuriSafe™ generates an alarm that's warns him about his predefined threats and opens a map of the danger area. Once TuriSafe™ **distress button** is pressed it will activate a set of actions such as sending automatic mail/SMS/call to family/local police, at time intervals with the tourist's details, the distress issue and a Real time location.




TuriSafe™'s primary markets are **Tourism, Real Estate and the Insurance industries**.

For example, the insurance companies can generate revenue and cut costs based on those derivatives: customer added value, claim rejection and **event prevention**. Insurance **Fraud detection** can be based on the user consent sharing of his data and location at the time of the claimed insurance event.



The unique IP Algorithm is based on the cutting-edge proven methodology in Criminology, called "**The Criminology of Place**". In a nutshell, it was found that more than 90% of all the crimes (nondomestic or workplace crimes) being held repetitively in the same locations the city, as well as driven mainly by the structure of the place.



At the moment we are negotiating with one of the biggest insurance companies in Israel who wants to deploy our solution as API in its App. by beginning of 2023. We are looking for an Investor of 250K\$ for a worth of 2M\$, so we could complete the global DB, develop the full offering for commercial use and initiate basic Marketing essentials, by Jan-Feb 2023.





Barimote is developing a data driven technology that will enable T2D (Type 2 Diabetes) patients to have a life free of diabetes and diabetic Rx medications. An become the market leader and standard of care for adult obesity related T2D.

Barimote technological solution:

By combining the Adjustable Gastric Banding Metabolic Surgery with Barimote’s Remote Monitoring & Real Time Training Adjustable Gastric Band (RMRTT-AGB) we will be able to provide OR-T2D patients the benefits of a life free of diabetes and Rx diabetic medications. The combination of eating behavior data, lifestyle data, glucose level and additional sensors with AI & ML will enable us to provide a life time follow-up, personalized medical advice and alerts of deviations, thus enabling them a life time free of diabetes and diabetic medications.





Barimote’s business model:

Metabolic Surgery is reimbursed in the US, UK, Canada, Australia and most of Western European counties at various levels and methods. For these countries with an ~ 130 million OR -T2D population we will use a B2B model through local distributors, strategic partners and subsidiaries. In countries with no reimbursement of Metabolic Surgeries such as China & India that have ~200 million OR-T2D adult population we intend to use a B2G model The expected streams of revenues will be from the device sales @ 5000US\$/unit, the procedures & device sales in B2G markets @ 7000 US\$/Case & a life time follow-up fee per patient @ 1200 US\$/ year.

Batimote’s technology traction:

We have 5 granted USPTO patents and more to come. We have done an in lab POC and we have shown the technology can identify the type of food in 9/10 food volumes passing through the sensing device. We have conducted a survey among 20 Metabolic surgeons and KOL 87% of them rated the Barimote core technology as important and highly important for their patients long term success. Barimote’s solution has a 24 years TLV 7 times lower than the 24 years TLV of the current health expanses in the US

For more information : www.barimote.com






AR AI PLATFORM FOR IMPROVED SHOPPER EXPERIENCE AND STORE MANAGEMENT

Making life easier for retailers, shoppers and brands. Providing a superior AI/AR engine using phones and HMD.


Clients: Sam's Club, Walmart, FairPrice, Action Link, Verizon.



87% of shoppers demand digital product content during their shopping journeys.

70% of shoppers purchase in-store post-pandemic.

Merchandisers are looking to improve labor and stock efficiency to meet demand.




weR META-STORE PRODUCT MARKET FIT

SaaS Retail Solution powered by the weR AR/AI engine.


Store Management :

- AR/AI Store Mapper : Digital Twin of retail space - connecting online to offline
- AR/AI Compliance : Improved shelf and stock availability, Increased labor efficiency.
- AR/AI Picker : 30% Increased Online Sales and labor efficiency.



Shopper Experience :

- In-Store AR/AI Platform for Brands : +50% Increased engagement, awareness and conversions.
- In-Store AR/AI Shopper : Incorporate the weR AR\AI engine in apps for a better shopping experience.
- Branded NFT Marketplace : Generates value for users on the shelves.



Company Snapshot : Founded in 2019, Team size - 8, Funding to date - \$225K, Total revenue - \$1M.

Participated programs and challenges : Google cloud for startups program, Verizon 5g retail prototyping challenge (NRF), EthAum accelerator program, FastForward with HE 2021- Finalist, AWE Startup pitch competition 2021



For further information: www.wer.io



The Intelligent Sleep Apnea Treatment

GLOBAL LIFE-THREATENING PROBLEM

Obstructive Sleep Apnea (OSA) is called “the silent killer”. The chronic disease causes people to stop breathing while they sleep. To avoid suffocation, the sufferer’s brain jolts their body to take a breath. The cycle repeats up to 100s of times nightly, disrupting sleep patterns.

The most common treatment prescribed for OSA is a technology invented over 40 years ago: CPAP (Continuous Positive Airway Pressure).

THERAPNEATM: TODAY’S MODERN OSA SOLUTION

Therapnea™ is our new and unique OSA therapy device. It overcomes CPAP therapy compliance problems through patented innovations and a disruptive approach to OSA treatment. Therapnea™ is an upper airway support device.

The device provides support to the pharynx walls and at the back of the tongue only during sleep apnea events, preventing airway collapse and obstruction.

Our product, Therapnea™ is a stent, which is introduced into the upper airway, to stop apnea and snoring. The stent is inserted into the upper airway ONLY after the patient is asleep and apnea events have started. Our patented technology overcomes the GAG reflex. Our product is a therapeutic device, but at the same time it is a diagnostic device as it collects information during the night (apnea, snoring, oxygen saturation, heart beep and more) and sends it in the morning to patient’s MD and to us, building huge data to enable future research on sleep.

Our technology is protected by patent, which is already granted in the USA, Russia, Israel, China, Hong-Kong, Australia and South Africa and is expected to be granted soon in Europe and India.

